Back to search results

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Myeloma · Multiple Myeloma · Refractory Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Brigham and Women's Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Omar Nadeem, MD) · Omar_Nadeem@dfci.harvard.edu · 617-632-4703
    Contact: Principal Investigator (Omar Nadeem, MD)

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (David Avigan, MD) · davigan@bidmc.harvard.edu · 617-667-9920
    Contact: Principal Investigator (David Avigan, MD)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Omar Nadeem, MD) · Omar_Nadeem@dfci.harvard.edu · 617-632-4703
    Contact: Principal Investigator (Omar Nadeem, MD)
Study leads

  • Omar Nadeem, MD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)